Merck & Co., operating as MSD, announced a strategic research collaboration with Isomorphic Labs to identify small-molecule drug candidates for a specific oncology target. Isomorphic Labs will utilize its proprietary IsoDDE platform for in-silico design, while MSD retains responsibility for preclinical development, clinical trials, manufacturing, and commercialization.
Merck & Co. (under its MSD trade name) announced an AI drug-discovery collaboration with privately held Isomorphic Labs for a single oncology target. The article states MSD will handle preclinical and clinical development, manufacturing and marketing, and that Isomorphic Labs receives an upfront payment and milestone royalties, but no monetary amounts are disclosed. Without a quantified deal value, this is a routine partnership announcement unlikely to move the share price materially.
- • Research collaboration on an oncology target announced 20 November 2026
- • MSD takes development, manufacturing and marketing rights to any resulting products
- • No upfront payment or milestone amounts are disclosed
- • Drug candidates may fail to gain regulatory approval or commercial success, as the forward-looking statement section warns